Researchers track lung cancer care in china
NCT ID NCT07316062
First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times
Summary
This study looks at medical records of 3000 people in China with early-stage non-small cell lung cancer (stages I to III). The goal is to understand what treatments patients receive, how often biomarker testing is done, and what happens to them over time. No new treatments are given—researchers simply review existing data to learn about current care patterns.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGBeijing, China
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Timing is everything: new study seeks best sequence for brain metastases treatment
- Real-World data reveals how lung cancer drug lorlatinib performs outside the lab
- New hope for advanced cancers? pfizer launches early trial of PF-08046033
- New hope for lung cancer patients whose current drug stops working
- New lung cancer drug shows promise in early trial
- New antibody EPI-326 enters first human trials for tough cancers